



SEVERE NAUSEA/VOMITING

Ondansetron (Zofran) Trial Study ALWAYS USE UNIVERSAL PRECAUTIONS

AUTHORITY

Division 2.5, Health and Safety Code, Sections 1797.220 & 1797.221

DEFINITION – Intractable Nausea and/or vomiting unrelieved by patient positioning

TREATMENT

- Maintain ABCs
- Provide Oxygen
- I.V. NS TKO if indicated.
- Consider fluid bolus 250cc N.S for volume depletion if patient has been experiencing significant vomiting; repeat as needed.
- Ondansetron **Adults and pediatric patients age 4 years or older:** 4 mg IM, PO (dissolvable tablet) or slow IV (over 30 sec)
- If additional doses of Ondansetron are required, Contact Base Hospital physician for consult.

CONTRAINDICATIONS

- Known sensitivity to Ondansetron (Zofran) or other 5-HT₃ antagonists including:
 - Granisetron (Kytril)
 - Dolasetron (Anzemet)
 - Palonosetron (Aloxi)

SIDE EFFECTS

- May cause hypotension and/or tachycardia

DOCUMENTATION

- In addition to currently required patient care documentation; each administration of Ondansetron will be documented on an "Ondansetron Trial Study Continuous Quality Improvement Form".